Tilray Traders Pile Into Options as Cannabis Rescheduling Deadline Looms
Published on 08/04/2026 at 07:25 | Redaktion boerse-global.de
Options desks are lighting up with Tilray activity, and the catalyst is clear: Washington's timeline on cannabis rescheduling is now measured in days, not months. The U.S. Drug Enforcement Administration has set an August 17 cutoff for post-hearing submissions on moving cannabis to the less restrictive Schedule III category, and derivatives traders are positioning accordingly.
The flurry of options trading on August 3 caught the attention of data services, with TipRanks flagging unusually active options classes at the market open. CNN's market data feed echoed the same signal. The interest follows a report on the company's global expansion strategy that had already stirred fresh investor attention days earlier.
Shares swung between $4.59 and $4.94 on that same session, closing at $4.83 — roughly 5 percent above the day's low. CNN data showed the stock up 6.61 percent at the open, trading at $4.60, six cents above the prior close. Volume, however, told a more cautious story: 2.87 million shares changed hands, well below the 5.6 million daily average. The stock remains pinned near the bottom of its 52-week range of $3.67 to $23.20, and still trades beneath both its 50-day and 200-day moving averages. The company's market capitalization stands at roughly $706 million, with a price-to-earnings ratio of negative 4.22.
The options surge is the latest chapter in a year defined by sensitivity to regulatory headlines. A rescheduling decision would open federally compliant medical distribution channels in the U.S., validating Tilray's strategy of building a U.S. "medical platform" model. But the downside risk is equally visible: any delay or derailment of the DEA process would freeze the company's U.S. expansion for months.
Should investors sell immediately? Or is it worth buying Tilray?
That regulatory overhang now intersects with a fractured analyst community. The August options activity follows Tilray's record fiscal 2026 results, which have done little to unify Wall Street's view. FactSet data shows three buy ratings against six holds, with zero sells. The median price target sits at $5, roughly 12 percent above current levels, while the average of $7.47 is skewed upward by a single outlier at $19. The low end of the range is $4.25.
Individual analyst calls remain scattered. Derek Lessard of TD Cowen reaffirmed a buy with a $5 target. Frederico Gomes at ATB and Aaron Grey of Alliance Global both stuck with hold ratings, targeting $8 and $5 respectively.
The fundamental picture is equally mixed. Management projects adjusted EBITDA of $68 million to $75 million for fiscal 2027, representing growth of roughly 11 to 23 percent over the prior year's $61.1 million. Revenue is expected to cross the $1 billion threshold, though management has declined to offer a specific revenue range. The earnings outlook, however, has deteriorated: consensus loss-per-share estimates for 2027 have widened from minus $0.39 to minus $0.47, underscoring that profitability remains unresolved even as the top line expands.
The options positioning also reflects a structural shift in how Tilray makes money. Non-cannabis segments now drive the majority of growth, with the beverage and distribution arm contributing $50.9 million of the $57.2 million quarterly revenue increase. Beverage sales grew 61 percent, distribution rose 15 percent, while cannabis managed just 5 percent growth. For fiscal 2026 as a whole, non-cannabis divisions generated 71 percent of revenue.
Tilray at a turning point? This analysis reveals what investors need to know now.
Gross profit tells a different story. Cannabis accounted for only 29 percent of sales but delivered 41 percent of gross profit — a margin advantage that explains why traders are hedging in both directions. A favorable Schedule III ruling would disproportionately boost the high-margin cannabis business, while beverages and distribution currently carry the revenue growth.
CEO Irwin Simon has told investors the company's next chapter won't hinge on any single product, market, or regulatory event. The options market, for now, seems to disagree — at least for the next two weeks. Until the August 17 deadline passes, expect the derivatives activity to stay elevated as traders position for what could be a defining moment for the stock's trajectory.
Ad
Tilray Stock: New Analysis - 4 August
Fresh Tilray information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
